DailyIQ
DailyIQ
Last updatedUpdating…

UTHR·United Therapeutics Corporation

$554.73
-4.82 (-0.86%)
After Hours
High
$563.12
Open
$561.20
Market Cap
23.00B
52W High
$640.00
Low
$550.23
P. Close
$554.73
P/E
18.69
52W Low
$452.69
Fwd P/E
16.48
DailyIQ Est.
$731.08
Inst. Own.
77.1%
Short Interest
4.43%
Days to Cover
3.5
NewEarnings release, scored · filed Nov 4, 2026tone +5.3 vs prior release · 76 lines scoredSee the breakdown
Technical Score (1D)
71
BULLISH
News Sentiment
57
BULLISH
On Nov 20, United Therapeutics announced that a patient received its investigational UThymoKidney device in a pig kidney transplant trial, marking the first successful transplant using the technology and supporting the company’s xenotransplantation strategy. The same day the company also reported that the first clinical xenotransplant of its UThymoKidney was performed in a patient with end‑stage renal disease during the EXTEND study, conducted at NYU Langone Health, demonstrating safety and feasibility for patients ineligible for conventional kidney transplantation. These milestones were said to potentially accelerate regulatory review and broaden treatment options for ESRD patients, advancing United Therapeutics’ pipeline. On Nov 19, United Therapeutics’ Executive Vice President and General Counsel Paul A. Mahon sold 8,300 shares worth $4.69 million, a transaction disclosed in an SEC filing and reported by MT Newswires and Yahoo Finance. The sale, occurring shortly after the company’s latest earnings release, was noted by some as a possible short‑term bearish signal, though no immediate operational or strategic changes were indicated.
LOW TARGET
$390 -29.7%
1 analysts
MEAN TARGET
$687 +23.9%
12 analysts
HIGH TARGET
$850 +53.2%
10 analysts
PRICE RANGE
$390.00 - $850.00
SB / B / H / S / SS
7/11/3/1/1
DAILYIQ EST.
$731.08 (+31.8%)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NMS
Country
United States
Symbol
UTHR
Description
United Therapeutics Corporation is a biotechnology firm focused on commercializing therapies for chronic and life-threatening illnesses, primarily in the United States and internationally. The company's core business revolves around treatments for pulmonary arterial hypertension (PAH), offering a portfolio of approved products like Tyvaso DPI, Tyvaso, Remodulin, Orenitram, and Adcirca, designed to manage symptoms and slow disease progression. Beyond PAH, United Therapeutics markets Unituxin for high-risk neuroblastoma and is developing innovative therapies, including RemoPro, Ralinepag, and Aurora-GT, expanding its pipeline for PAH and other indications. Strategic collaborations with other entities, such as DEKA Research & Development Corp. and MannKind Corporation, support the company's efforts to enhance drug delivery and expand its product offerings. This focus on specialized therapies positions United Therapeutics to address unmet medical needs and improve patient outcomes.
Bought (1Y)
1,500 shares
$864K
Sold (1Y)
1,447,646 shares
$783.3M
ROTHBLATT MARTINE AChairperson & CEO
Option Exercise5,410 shares2026-11-18
ROTHBLATT MARTINE AChairperson & CEO
Sell40 shares2026-11-18
ROTHBLATT MARTINE AChairperson & CEO
Sell77 shares2026-11-18
ROTHBLATT MARTINE AChairperson & CEO
Sell123 shares2026-11-18
ROTHBLATT MARTINE AChairperson & CEO
Sell439 shares2026-11-18
87/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
87.9%
Net Margin
41.9%
Revenue CAGR
15.3%
Current Ratio
6.60x
Return on Equity
18.8%
Earnings Summary
In the most recent quarters, United Therapeutics reported Q4 2025 earnings with EPS of $7.70 versus an estimate of $7.33, a beat, while revenue of $790.2 million fell short of the $829.3 million estimate, indicating a slight revenue deceleration. Q2 2026 saw EPS of $7.27 beating the $6.86 estimate, yet revenue of $783.3 million again missed the $821.8 million forecast, continuing the pattern of earnings beats coupled with revenue shortfalls. The Q3 2026 quarter reversed this trend, with EPS of $5.71 below the $6.55 estimate but revenue of $832.5 million surpassing the $796.8 million estimate, demonstrating volatility in earnings versus revenue performance. Historically, United Therapeutics has shown a YoY revenue growth trajectory, with consistent EPS beats in the last four quarters despite occasional revenue misses, suggesting disciplined cost management and pricing power. Recent news highlights a successful pig kidney transplant using the UThymoKidney device and the first clinical xenotransplant in a patient with end‑stage renal disease, milestones that could accelerate regulatory review and broaden treatment options for ESRD patients, potentially impacting future revenue streams.

EPS

EstBeatMiss
$5.41$6.06$6.71$7.35$8.00Q4'24Q4'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$6.82 - -
Q3'26$6.55$5.71-12.9%
Q2'26$6.86$7.27+5.9%
Q4'25$7.33$7.70+5.1%
Q4'24$6.27$6.19-1.2%

Revenue

EstBeatMiss
$714M$762M$810M$858M$906MQ4'24Q4'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$883M - -
Q3'26$797M$833M+4.5%
Q2'26$822M$783M-4.7%
Q4'25$829M$790M-4.7%
Q4'24 - $736M -

Market Data

UTHR Stock Snapshot

BULLISH71/100
$554.73+$0.00 (0.0%)
Market cap
23.00B
P/E ratio
18.7
Day range
$550.23 – $563.12
News sentiment
57/100 · Neutral
Analyst target
$687.14 (+23.9%)
Consensus
Buy · 23 analysts
52-week range+22.5% off low · -13.3% from high
$452.69$640.00
Price $554.73 DailyIQ Est. $731.08

Trend, momentum and range position line up bullish on UTHR at the moment. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What UTHR's own history says about today's numbers

Realized volatility (21d)
32.5% 59th pct
Below its peak
-8.8%
vs 200-day average
+2.8%
Up days (1y)
47%

United Therapeutics Corporation is currently running 32.5% annualised volatility over the last 21 sessions. Measured against UTHR's own 13 years of daily returns rather than a market-wide average, that is the 59th percentile — close to its own typical level, against a typical reading of 30.1%.

UTHR is trading -8.8% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -27.8%, and the deepest was -41.1% in 2019. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +2.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 49th percentile — close to the gap it normally carries. Over the past year UTHR closed higher on 47% of sessions, and it is currently 7 sessions into a falling streak.

On November specifically: over 13 years of records, UTHR finished the month higher 8 of 13 times, with a median return of +2.6% and an average of +3.8%. Its strongest month historically has been October at +5.2% on average, its weakest September at -1.8%.

Overnight risk is measurable too: UTHR has opened more than 2% away from the prior close in 121 of 3,267 sessions (3.7% of the time), with the largest gaps running +51.0% and -12.9%.

Across the last 3 dated reports on file, UTHR moved an average of 5.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -5.9% and a largest of -7.0%.

All figures computed from 3,268 daily closes between 2013-11-22 and 2026-11-20, split-adjusted, recomputed daily. Percentiles are against UTHR's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of UTHR's sector?

United Therapeutics Corporation sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#5 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for UTHR?

CallsPuts

For United Therapeutics Corporation's nearest expiry (2026-12-18, 26 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.15), with at-the-money implied volatility around 43.9%. The options market is pricing roughly a ±11.5% move by that expiry — a range of about $491.20–$618.26.

Put/call ratio (2026-12-18)
1.15
ATM implied volatility
43.9%
Total open interest
666
Expected move by 2026-12-18
±11.5% ($491.20–$618.26)

Analyst Rating Changes

Are analysts turning bullish or bearish on UTHR?

TD Cowen most recently reiterated its rating on United Therapeutics Corporation to Buy on Nov 5, 2026 with a price target of $700 (from $675). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
TD Cowen: Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Nov 5, 2026TD CowenMaintainedBuy$675 → $700
Nov 5, 2026RBC CapitalMaintainedOutperform$697 → $725
Nov 5, 2026Wells FargoMaintainedOverweight$700 → $703
Nov 4, 2026BTIGMaintainedBuy$728 → $768
Oct 28, 2026JP MorganMaintainedOverweight$710 → $695
Oct 22, 2026RBC CapitalMaintainedOutperform$708 → $697
Oct 19, 2026Leerink PartnersMaintainedOutperform$685 → $725
Oct 8, 2026RBC CapitalMaintainedOutperform$677 → $708
Oct 7, 2026Morgan StanleyMaintainedEqual-Weight$515 → $566
Oct 1, 2026BTIGUpgradeNeutral → Buy$728
Sep 24, 2026Goldman SachsInitiatedSell$321
Aug 6, 2026RBC CapitalMaintainedOutperform$704 → $677

Earnings Release, Scored

What did United Therapeutics Corporation's latest earnings release say?

Filed Nov 4, 2026 · SEC Form 8-K, Exhibit 99

Tone58.9/ 100+5.3 vs prior release
Hedging words0.33per 100 words-0.20 vs prior release
Tone, last 3 releasesScale 46–66

Most important lines

  1. 1

    of therapies and their potential to exponentially increase the number of patients that we can serve; new opportunities across cardiopulmonary and respiratory medicine; the timing of the final settlement of the September 2026 ASR; the timing, structure and use of our share repurchase program; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.

    New this quarter
  2. 2

    Our ETR for the three months ended September 30, 2026 increased compared to our ETR for the three months ended September 30, 2025, primarily due to nondeductible IPR&D expense related to the acquisition of Thymmune, which was capitalized for tax purposes into the basis of the stock acquired.

    New this quarter
  3. 3

    Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025.

Peers & ETF holders

UTHR peers & ETF holders

News & sentiment

What is the news saying about UTHR?

UTHR fell 0.8% over the month to Nov 20. News tone held between 33 and 73 from Oct 20 to Nov 16, then jumped to 68 on Nov 17.

Daily close and news tone, Oct 20 to Nov 20
$550$575$600Oct 20: tone 73Oct 21: tone 42Oct 22: tone 49Oct 23: tone 70Oct 26: tone 37Oct 27Oct 28: tone 59Oct 29: tone 45Oct 30: tone 43Nov 2: tone 37Nov 3Nov 4: tone 52Nov 5: tone 65Nov 6: tone 37Nov 9: tone 53Nov 10: tone 57Nov 11: tone 61Nov 12: tone 48Nov 13Nov 16: tone 33Nov 17: tone 68Nov 18: tone 50Nov 19: tone 42Nov 20: tone 61Oct 20News toneNov 20123
  1. Oct 22 +3.8%same day: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
  2. Nov 5 -7.0%same day: What Is Drawing Attention To United Therapeutics (UTHR) Today?
  3. Nov 9 +3.6%same day: United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

Technical analysis

How strong is UTHR's momentum right now?

On the daily chart UTHR ranks at the 71st percentile for momentum against 1,063 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling UTHR?

95 of the 195 tracked managers added to UTHR in their latest 13F and 93 trimmed. Together they own 77.1% of the company, worth $17.3B. BlackRock and State Street alone hold 18.2%.

95adding93trimming7unchanged
Largest holders by stake, latest 13FBar = share of UTHR
  1. $3.0B positionAdded 5.3% last quarter
  2. $1.1B positionAdded 2.9% last quarter
  3. $1.0B positionAdded 0.6% last quarter
  4. $1.0B positionTrimmed 0.4% last quarter
  5. $1.0B positionAdded 37.7% last quarter
  6. $908.2M positionTrimmed 1.9% last quarter
  7. 7Amundi2.38%
    $535.8M positionAdded 351.3% last quarter
  8. $527.2M positionTrimmed 2.2% last quarter
  9. $503.1M positionAdded 204.7% last quarter
  10. $436.9M positionAdded 70.4% last quarter
Full holdings history

Congressional trading

Is Congress trading UTHR?

1 member of Congress disclosed 3 UTHR trades between Oct 30 and Oct 31, 2025: 1 buy and 2 sells, about $24.0K in estimated value.

BuysSellsOct
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has UTHR done against its peers?

Over the six months to Nov 20, UTHR returned −1.6%. Of the 15 related stocks and ETFs, 14 did better, led by MRNA at +304.6%.

Change since May 20, through Nov 20
−200%0%+200%+400%+600%May 20JulAugSepOctNovNov 20MRNA +304.6%UTHR −1.6%ALNY −51.5%